A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...

Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...

Learn when hypertrophic cardiomyopathy becomes severe and how a cardiologist guides you through heart transplant evaluation ...

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...

A phase 3 clinical trial found that mavacamten can improve flow through the left ventricle, with the potential to spare some patients with hypertrophic cardiomyopathy from open-heart surgery.

Is your outdated human capital management software (HCM) so inefficient it’s stifling your company’s growth? In my years of working in human resources, I’d say that bad software is the No. 1 problem ...

Hypertrophic cardiomyopathy (HCM) affects one in 500 people in the general population. In most cases, HCM is caused by genetic mutations. Doctors usually discover HCM during cardiac testing (an ...

Hypertrophic cardiomyopathy (HCM) is usually the result of genetic changes that affect the heart muscle. These changes cause the walls of the heart muscle to become excessively thick, which makes it ...

HCM TradeSeal launches TeamMate, an AI assistant that helps contractors navigate certified payroll compliance and ...

Leaders in the SMB HCM market include ADP Workforce Now, BambooHR, HiBob, isolved, Paycor, and UKG Ready. MIAMI, March 17, ...